Inhibition of thrombin activity by a covalent-binding aptamer and reversal by the complementary strand antidote

抄録

Alleviating the potential risk of irreversible adverse drug effects has been an important and challenging issue for the development of covalent drugs. Here we created a DNA-aptamer-type covalent drug by introducing a sulfonyl fluoride warhead at appropriate positions of the thrombin binding aptamer to create weaponized covalent drugs. We showed the de-activation of thrombin by the novel modality, followed by its re-activation by the complementary strand antidote at an arbitrary time. We envision that such on-demand reversal of covalent drugs will alleviate the major concern of potentially irreversible ADEs and accelerate the translational application of covalent aptamer drugs.

source:https://doi.org/10.1039/D0CC08109D

収録刊行物

  • Chemical Communications

    Chemical Communications 57 (20), 2483-2486, 2021-03-11

    The Royal Society of Chemistry (RSC)

被引用文献 (2)*注記

もっと見る

参考文献 (40)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ